Cipla signs second agreement with MPP for TAF

To the cause of HIV treatment

Cipla announced that two months after signing a licence with Gilead Sciences, Inc. for the company's novel investigational medicine tenofovir alafenamide (TAF), MPP announced six new sub-licences with Aurobindo, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs to allow generic manufacture of TAF for 112 developing countries.

MPP's announcement comes one day after Gilead released positive results on two of its TAF Phase III studies, suggesting that the medicine has the potential to play a large role in the international community's efforts to scale-up HIV treatment.

Powered by Capital Market - Live News